Dr. Nicolas Jacquelot
Positions
Assistant Professor
Cumming School of Medicine, Department of Biochemistry and Molecular Biology
Assistant Professor
Cumming School of Medicine, Department of Microbiology, Immunology and Infectious Diseases
Affiliations
Full Member
Arnie Charbonneau Cancer Institute
Full Member
Immunology Research Group
Contact information
Web presence
Phone number
Office: 403.210.9160
Location
Office: HMRB311
For media enquiries, contact
Kelly Johnston
Senior Communications Specialist
Please submit your media request here
Preferred method of communication
Administrative Assistant
Monica Mauchline
Email: monica.mauchline@ucalgary.ca
Background
Educational Background
BSc. Cellular and Molecular Biology, Universite de Lorraine,
MSc. Immunology, Universite Paris Sud XI,
PhD. Cancer Immunology, Universite Paris Sud XI,
Biography
Dr. Nicolas Jacquelot is a cancer immunologist who completed his PhD in the laboratory of Professor Laurence Zitvogel at Gustave Roussy Institute. His work has shed light on new molecular and cellular pathways that critically influence patient prognosis and immunotherapy outcomes. He pursued his postdoctoral training in Professor Gabrielle Belz’s group at The Walter and Eliza Hall Institute of Medical Research and in Professor Pamela Ohashi’s laboratory at the Princess Margaret Cancer Centre. In January 2023, Dr. Jacquelot established his research laboratory at the University of Calgary in the Cumming School of Medicine. His research has revealed the role and function of innate lymphoid cells in anti-tumor immunity and immunotherapy responses. Altogether, his studies have provided a better understanding of the role and function of immune lymphocytes, particularly T cells and the recently discovered innate lymphoid cells in cancer.
Research
Areas of Research
- Cancer
- Immunology
- Immunotherapy
- Innate Immunity
Our laboratory is studying the role and function of the immune system in cancer. We examine the contribution of the innate lymphoid cells (ILCs) to tumor development and therapy responses. Despite their critical role in fighting infections and promoting inflammation driving autoimmune diseases, how ILCs, considered as the innate counterpart of adaptive lymphocytes, impact tumor development, progression and cancer treatments remain vastly unknown. We leverage our expertise in mouse models, tissue biology, tumor immunology, flow-cytometry, microscopy, and multi-omics analyses to perform experiments that test the role and function of ILCs in cancer. Ongoing research efforts include (i) investigating the cellular and molecular pathways influencing ILC function in tumors, (ii) dissecting ILC signaling pathways and communication with other cells within the tumor microenvironment, and (iii) determining ILC prognostic values and therapeutic potential in cancer. Our overreaching goal is to improve cancer patient prognosis through the development of ILC-based treatments.
Courses
| Course number | Course title | Semester |
|---|---|---|
| MDSC 567 | Advanced topics in Immunology | |
| MDSC 639.02 | Cellular and Molecular Immunology | |
| MDSC 639.04 | Basic Principles in Inflammation |
Projects
Our laboratory is studying the role and function of the immune system in cancer. We examine the contribution of the innate lymphoid cells (ILCs) to tumor development and therapy responses. Despite their critical role in fighting infections and promoting inflammation driving autoimmune diseases, how ILCs, considered as the innate counterpart of adaptive lymphocytes, impact tumor development, progression and cancer treatments remain vastly unknown. We leverage our expertise in mouse models, tissue biology, tumor immunology, flow-cytometry, microscopy, and multi-omics analyses to perform experiments that test the role and function of ILCs in cancer. Ongoing research efforts include (i) investigating the cellular and molecular pathways influencing ILC function in tumors, (ii) dissecting ILC signaling pathways and communication with other cells within the tumor microenvironment, and (iii) determining ILC prognostic values and therapeutic potential in cancer. Our overreaching goal is to improve cancer patient prognosis through the development of ILC-based treatments.
Publications
More Information
Pauline Mauchline, Administrative Assistant
Amisha Verma, Undergraduate Student
Ammar Sleitin, Undergraduate Student
Hobin Seo, MSc Graduate Student
Megan Kinzel, MSc Graduate Student
Zahra Ikra, PhD Candidate
Huiyang Yu, PhD Candidate (University of Queensland, co-supervised with Dr. Belz)
Kaelie Bittorf, MD Student
Dr. Amrita Kaur, Laboratory Technician/Laboratory Manager
Dr. Qiutong (Angela) Huang, Postdoctoral Fellow
Are you the profile owner?
Login to edit.